MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns ... and non-surgical alternative for eschar removal in pediatric burn patients ...

Typical lesions progress from red or gray macules or papules, to red or gray macules or papules with a central eschar or ulceration ... was easily removed with debridement scissors (see Figure ...

On examination, the left buttock decubitus ulcer had a black eschar with foul smell (Figure ... and bedside limited debridement with collection of a swab culture (BBL CultureSwab collection ...

YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its ...

MediWound’s first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep ... in Phase III development for the debridement of chronic wounds.

These results reinforce NexoBrid’s clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, validating its significance as a ...

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep ... in Phase III development for the debridement of chronic wounds.

Faster eschar removal: NexoBrid achieved complete ... a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx ...